Molecular Profile Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Gamma secretase inhibitor LY900009 Phase I Actionable In a Phase I trial, LY900009 demonstrated manageable safety and some preliminary activity in patients with advanced solid tumors, with treatment resulting in no responses, but stable disease in 14% (5/35) of patients (PMID: 26798966). 26798966
Unknown unknown brain stem glioma not applicable Gamma secretase inhibitor JQ1 + MRK-003 Preclinical - Cell culture Actionable In a preclinical study, the combination of MRK-003 and JQ1 resulted in increased apoptosis of diffuse pontine glioma cell lines in culture, compared to either agent alone (PMID: 26115193). 26115193
Unknown unknown juvenile astrocytoma not applicable Gamma secretase inhibitor MRK-003 Preclinical Actionable In a preclinical study, MRK-003 inhibited HES1 expression in pediatric low-grade astrocytoma cell lines in culture and decreased migration in 1 of 2 cell lines, but did not have a significant effect on cell growth (PMID: 25575134). 25575134
Unknown unknown brain stem glioma not applicable Gamma secretase inhibitor MRK-003 Preclinical - Cell culture Actionable In a preclinical study, MRK-003 increased apoptosis and decreased growth of diffuse pontine glioma cell lines in culture (PMID: 26115193). 26115193
Unknown unknown brain stem glioma not applicable Gamma secretase inhibitor MRK-003 + Radiotherapy Preclinical - Cell culture Actionable In a preclinical study, MRK-003 enhanced sensitivity of diffuse pontine glioma cell lines to radiotherapy in culture, resulting in increased apoptosis (PMID: 26115193). 26115193
Unknown unknown esophagus adenocarcinoma not applicable NOTCH Inhibitor (Pan) IMR-1 Preclinical - Cell line xenograft Actionable In a preclinical study, IMR-1 treatment of esophageal adenocarcinoma cells resulted in decreased colony formation in culture and inhibition of tumor growth in xenograft models (PMID: 27197169). 27197169
Unknown unknown Her2-receptor positive breast cancer not applicable NOTCH Inhibitor (Pan) BMS-906024 Preclinical Actionable In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of ERBB2 (HER2)-positive breast cancer xenografts (PMID: 26005526). 26005526
Unknown unknown colon carcinoma not applicable NOTCH Inhibitor (Pan) BMS-906024 Preclinical Actionable In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of colon carcinoma xenografts (PMID: 26005526). 26005526
Unknown unknown non-small cell lung carcinoma not applicable NOTCH Inhibitor (Pan) BMS-906024 Preclinical Actionable In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of non-small cell lung carcinoma xenografts (PMID: 26005526). 26005526
Unknown unknown ovarian carcinoma not applicable NOTCH Inhibitor (Pan) BMS-906024 Preclinical Actionable In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of ovarian carcinoma xenografts (PMID: 26005526). 26005526
Unknown unknown glioblastoma multiforme not applicable NOTCH Inhibitor (Pan) BMS-906024 Preclinical Actionable In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of glioblastoma xenografts (PMID: 26005526). 26005526
Unknown unknown neuroblastoma not applicable NOTCH Inhibitor (Pan) BMS-906024 Preclinical Actionable In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of neuroblastoma xenografts (PMID: 26005526). 26005526
Unknown unknown triple-receptor negative breast cancer not applicable NOTCH Inhibitor (Pan) BMS-906024 Preclinical Actionable In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of triple-negative breast cancer xenografts (PMID: 26005526). 26005526
Unknown unknown pancreatic carcinoma not applicable NOTCH Inhibitor (Pan) BMS-906024 Preclinical Actionable In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of pancreatic carcinoma xenografts (PMID: 26005526). 26005526
Unknown unknown Advanced Solid Tumor not applicable NOTCH Inhibitor (Pan) LY3039478 Phase I Actionable In a Phase I trial, LY3039478 treatment resulted in 80% inhibition of plasma A-beta and more than 50% inhibition of Notch1-regulated genes in patients with advanced solid tumor, leading to partial response in 0.9% (1/110) and stable disease in 32.7% (36/110) of the patients (PMID: 30060061; NCT01695005). 30060061 detail...
Unknown unknown Advanced Solid Tumor not applicable NOTCH Inhibitor (Pan) LY3039478 Phase I Actionable In a Phase I trial, treatment with LY3039478 was well-tolerated and demonstrated some preliminary efficacy in patients with advanced solid tumors (J Clin Oncol 33, 2015 (suppl; abstr 2533)). detail...
Unknown unknown leiomyosarcoma not applicable NOTCH Inhibitor (Pan) LY3039478 Phase I Actionable In a Phase I trial, treatment with LY3039478 resulted in tumor necrosis in a patient with leiomyosarcoma (European Journal of Cancer, Volume 69, S15). detail...
Unknown unknown adenocarcinoma not applicable NOTCH Inhibitor (Pan) LY3039478 Phase I Actionable In a Phase I trial, a patient with adenoid cystic carcinoma demonstrated a metabolic response when treated with LY3039478 (European Journal of Cancer, Volume 69, S15). detail...
Unknown unknown testicular cancer not applicable NOTCH Inhibitor (Pan) LY3039478 Phase I Actionable In a Phase I trial, a patient with testicular cancer demonstrated a metabolic response when treated with LY3039478 (European Journal of Cancer, Volume 69, S15). detail...
Unknown unknown Advanced Solid Tumor not applicable NOTCH Inhibitor (Pan) CB-103 Preclinical - Pdx Actionable In a preclinical study, CB-103 treatment resulted in antitumor efficacy in in vivo models and patient derived xenograft (PDX) models with advanced solid tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 411P). detail...
Unknown unknown Advanced Solid Tumor not applicable NOTCH1 Antibody Brontictuzumab Phase I Actionable In a Phase I trial, Brontictuzumab (OMP-52M51) treatment in patients with advanced selected solid tumors was well-tolerated, demonstrated target engagement, and resulted in unconfirmed partial response in 5% (2/36) of patients (both adenoid cystic carcinoma with high NICD1 expression); stable disease (SD) in 28% (10/36), with 4 patients, all with high NICD1 expression, demonstrating SD for greater than 6 months; and a median progression-free survival of 65 days (PMID: 29726923; NCT01778439). 29726923
Unknown unknown renal cell carcinoma not applicable NOTCH1 Antibody 23814 Preclinical - Pdx Actionable In a preclinical study, treatment with 23814 resulted in tumor growth inhibition in a renal cell carcinoma patient-derived xenograft (PDX) model (PMID: 25995436). 25995436
Unknown unknown fibrosarcoma not applicable NOTCH1 Antibody 23814 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with 23814 resulted in partial inhibition of tumor growth in a fibrosarcoma cell line xenograft model (PMID: 25995436). 25995436
Unknown unknown fibrosarcoma not applicable NOTCH1 Antibody 23814 + Tivozanib Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with the combination of 23814 and Tivozanib (AV-951) resulted in tumor growth inhibition in a fibrosarcoma cell line xenograft model, with increased efficacy over either agent alone (PMID: 25995436). 25995436
Clinical Trial Phase Therapies Title Recruitment Status